Last SFr.262.10 CHF
Change Today +2.10 / 0.81%
Volume 1.0M
ROG On Other Exchanges
Symbol
Exchange
OTC US
OTC US
Xetra
Xetra
SIX Swiss Ex
Mexico
Frankfurt
As of 8:17 AM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Daniel O'Day

Chief Operating Officer of Pharmaceuticals division, Roche Holding AG
AgeTotal Calculated CompensationThis person is connected to 83 board members in 3 different organizations across 8 different industries.

See Board Relationships
50SFr.8,533,289
As of Fiscal Year 2014

Background*

Mr. Daniel O'Day serves as Chief Operating Officer of Pharmaceuticals at Roche Holding AG. Mr. O'Day serves as the Chief Operating Officer of Roche Diagnostics GmbH and Hoffmann-La Roche Ltd. Mr. O'Day served as the Chief Executive Officer and President of Roche Molecular Diagnostics at Roche Carolina Inc. and Roche Holding AG. He served as the Chief Operating Officer of Roche Pharma AG since September 1, 2012. Mr. O'Day served as the Chief Executive Officer and President ...

Read Full Background

Corporate Headquarters*

Konzern-Hauptsitz
Basel, Basel-Stadt 4070

Switzerland

Phone: 41 61 688 11 11
Fax: 41 61 691 93 91

Board Members Memberships*

Director
Director
2013-Present
Director

Education*

MBA 1997
Columbia University
BS 1986
Georgetown University

Other Affiliations*

Annual Compensation*

SalarySFr.2,000,000
BonusSFr.3,000,000
Total Annual CompensationSFr.5,000,000

Stock Options*

Restricted Stock AwardsSFr.2,464,560
All Other CompensationSFr.1,068,729
Total Value of OptionsSFr.7,916,677
Total Number of Options116,229

Total Compensation*

Total Annual Cash CompensationSFr.6,068,729
Total Short Term CompensationSFr.5,000,000
Other Long Term CompensationSFr.3,533,289
Total Calculated CompensationSFr.8,533,289
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ROG:VX SFr.262.10 CHF +2.10

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
John C. Martin Ph.D.Chairman and Chief Executive Officer
Gilead Sciences Inc.
$1.6M
Marijn E. Dekkers Ph.D.Chairman of Management Board and Chief Executive Officer
Bayer AG
€3.2M
Ian C. Read Chairman, Chief Executive Officer and Chairman of Executive Committee
Pfizer Inc.
$1.8M
Kenneth C. Frazier Chairman, Chief Executive Officer and President
Merck & Co. Inc.
$1.5M
Serge Weinberg Chairman, Interim Chief Executive Officer, Chairman of Appointments & Governance Committee and Chairman of Strategy Committee
Sanofi
€700.0K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROCHE HOLDING AG-GENUSSCHEIN, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.